- Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filingCompass Pathways said Tuesday that patients in the second of its two pivotal psilocybin trials maintained their response to treatment for at least six months, keeping the company on track to comple…Endpoints · 17d ago↗ source
- Hengrui, Kailera's GLP-1 pill posts encouraging efficacy but high side effect rates in late-stage China trialsThe GLP-1 pill being developed by Hengrui Pharma and Kailera Therapeutics posted decent results in two late-stage China-based trials — one in obesity and the other in diabetes. But the safety pro…Endpoints · 17d ago↗ source
- Novartis, Vertex and Ipsen extend pharma M&A spree from 2026's first halfBiopharma's M&A engine is revved up and shows no signs of cooling off. Four companies have announced acquisitions in the first six days of July, forging deals that could pay out as much as $1…